Allogene Therapeutics
Clinical trials sponsored by Allogene Therapeutics, explained in plain language.
-
Off-the-Shelf CAR t cells show promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a new type of CAR T cell therapy called ALLO-501A, which is made from donor cells and does not need to be custom-made for each patient. It is for adults with large B-cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma that has come back or no…
Phase: PHASE1, PHASE2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
Experimental cell therapy targets Hard-to-Treat kidney cancer
Disease control OngoingThis early-phase study tests an experimental cell therapy called ALLO-316 in adults with advanced or metastatic clear cell kidney cancer who have already tried standard treatments. Participants receive the therapy after a short course of chemotherapy to prepare their immune syste…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 17, 2026 06:52 UTC